Skip to main content
. 2022 Nov 17;2022(11):CD014963. doi: 10.1002/14651858.CD014963.pub2

7.1. Analysis.

7.1

Comparison 7: Subgroup analysis: high‐income countries versus low‐ and middle‐income countries for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days